AC Immune SA Ratios

Ratios Dec2014 Dec2015 Dec2016 Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024 Sep2025
Profitability
EBT Margin 35.50%3,052.71%-30.57%-130.39%-737.14%41.12%-401.28%-13,983.33%-1,797.71%-366.35%-186.43%
EBIT Margin 35.41%2,804.82%-45.04%-111.28%-716.87%40.30%-396.99%-15,136.02%-1,800.43%-362.30%-191.80%
EBITDA Margin 35.41%2,761.60%-46.24%-114.14%-730.76%39.94%4.70%-13,800.77%-1,685.31%-378.10%-197.57%
Operating Margin 35.41%2,804.82%-45.04%-111.28%-716.87%40.30%-396.99%-15,136.02%-1,800.43%-362.30%-191.80%
Net Margin 0.00%0.07%0.00%0.00%-0.01%0.00%-401.28%-13,983.91%-1,798.04%-366.41%-186.44%
FCF Margin -57.86%6,602.41%-28.19%-118.85%-664.58%48.27%-396.75%-13,088.89%-1,901.07%-416.38%238.99%
Efficiency
Assets Average 118.45M144.95M165.66M249.93M283.22M275.10M239.56M199.55M234.29M238.50M
Equity Average 48.73M107.09M130.40M148.45M226.88M256.81M246.11M214.64M178.26M154.36M102.84M
Invested Capital 25.68M71.79M151.78M128.45M191.46M290.27M255.49M277.56M189.06M199.44M150.56M78.06M
Asset Utilization Ratio 0.200.140.040.450.060.000.020.080.130.12
Leverage & Solvency
Interest Coverage Ratio -0.00M-0.00M-153.33-148.3523.12-332.93-135.99-199.57-304.68-393.82
Debt to Equity 0.000.000.000.09
Debt Ratio 0.000.000.000.08
Equity Ratio 0.890.910.890.900.910.900.890.910.880.490.36
Times Interest Earned -0.00M-0.00M-153.33-148.3523.12-332.93-135.99-199.57-304.68-393.82
Valuation
Enterprise Value -3.71M-77.41M532.96M600.63M116.67M232.99M301.88M143.88M45.06M307.41M81.43M155.23M
Market Capitalization 685.25M726.70M304.03M524.57M551.75M360.80M172.30M423.58M269.57M290.82M
Return Ratios
Return on Sales 0.35%30.53%-0.31%-1.30%-7.37%0.41%-4.01%-139.84%-17.98%-3.66%-1.86%
Return on Capital Employed -0.10%-0.17%-0.33%0.19%-0.25%-0.34%-0.32%-0.33%-0.50%
Return on Assets -0.06%-0.18%-0.31%0.18%-0.24%-0.29%-0.31%-0.31%-0.25%
Return on Equity 0.42%-0.07%-0.21%-0.34%0.20%-0.27%-0.32%-0.34%-0.34%-0.37%